INDUSTRY EXPERTS INCLUDING:

Transcription

1 INDUSTRY EXPERTS INCLUDING: CANCER MICROBI ME CONGRESS 8-9 MAY, BOSTON, USA INCORPORATING THE POTENTIAL OF THE MICROBIOME INTO THE GROWING FIELD OF IMMUNO-ONCOLOGY Discover how the microbiome interacts with immunotherapies such as PD1 to improve the efficacy of immuno-oncology drugs David Cook Seres Therapeutics Bruce Roberts Vedanta Marina Walther-Antonio, Ph.D. Mayo Clinic 2 conference days 20 speakers 80+ attendees Build the foundations of interdisciplinary collaboration between the fields of microbiology, immunology & oncology to accelerate this pioneering field. Learn how to use the microbiome to determine how to better stratify patients, improve patient outcomes & further the potential of immunotherapy. Susan Erdman MIT Dedicated poster session

2 DISCOVER THE POTENTIAL OF THE MICROBIOME IN CANCER DRUG INTERACTIONS The gut microbiome has been proven to affect immunotherapies such as checkpoint inhibitors. Vancheswaran Gopalakrishnan, Wargo lab, MD Anderson Presenting on data published in Science on the modulation of response to anti PD-1 immunotherapy in melanoma patients. PREDICTION & DIAGNOSTICS The microbiota of cancer patients can be screened for known carcinogenic bacteria and bacterial metabolites to prevent & predict cancer initiation. Pierre Belichard, CEO, Enterome Enterome has been developing methods to identify microbiome-derived biomarkers, drug targets, and bioactive molecules as potential treatments and companion diagnostics for cancer THERAPEUTICS There has been huge potential demonstrated in the use of bugs as drugs as standalone therapies and in combination with immunotherapies and chemotherapy. David Cook, Executive Vice President of R&D and Chief Scientific Officer, Seres Therapeutics David will be presenting on the development of microbial therapeutics as immunotherapies and Seres collaboration with The Parker Institute & MD Anderson on SER-401 therapeutic. MECHANISMS Tumor-microbe interactions are not yet fully understood, and the mechanisms by which they affect carcinogenesis are still being researched. James Goedert, Senior Investigator, National Cancer Institute - NIH Dr Geodert is a senior investigator in infections and immunoepidemiology and a leading expert in the epidemiology of infection-associated malignancies, retired after 36 years with NCI. He will be presenting on the role of the microbiome in carcinogenesis

3 WHO YOU WILL MEET SOME OF OUR PAST ATTENDEES This congress will bring together international delegates from the fields of immunology, oncology & microbiology, within biopharma companies, academia, research & biotechnology companies. Academia improve knowledge levels, build partnerships, collaborate, discuss work Physicians/clinicians understand how their patients can benefit and how to stratify patients, learn more about the therapies in a clinical setting & how to improve patient outcomes Pharmaceutical companies learn about the current research in academia and improve current immunotherapies through collaboration Biotechnology companies build relationships, partner and discover recent advancements Service Providers - meet target market who need their services, understand competition. INTERESTED IN SPONSORSHIP OPPORTUNITIES? Far from the typical meet-and-greet exhibition experience, you as a sponsor or exhibitor will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list. With our extensive marketing experience and strategy, your partnership with the conference will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. SPONSORS INCLUDE: Sponsorship opportunities include exhibition, presentations, branding and an innovation showcase. Get in touch to find out ways to get involved. Contact our team to find out more about each package mg@kisacoreseach.com or by calling +44 (0)

4 SPEAKER FACULTY James Goedert MD Division of Cancer Epidemiology and Genetics, National Cancer Institute NIH H Rex Gaskins Cancer Center at Illinois University of Illinois Susan Erdman Principal Research Scientist and Assistant Director MIT Dario A. Gutierrez Immuno-Biology Lead Merck Vancheswaran Gopalakrishnan Wargo Lab MD Anderson Loïc Vincent Head, Oncology & Immunology Research Partnerships Takeda Bret Wallace Scientist Symberix Halle Zhang Director, Translational Sciences BioMed Valley Discoveries Marina R Walther-Antonio, Ph.D. Assistant Professor, Microbiome Program, Mayo Clinic David Cook Executive Vice President of R&D and Chief Scientific Officer Seres Therapeutics Bruce Roberts Chief Scientific Officer Vedanta Biosciences Pierre Belichard CEO Enterome Marcel Van Den Brink Lab Head, Immunology Program Memorial Sloane Kettering

5 AGENDA DAY ONE MORNING SESSION: THE MICROBIOME IN CANCER INITIATION & PROGRESSION 8:00 REGISTRATION 10:25 BREAK 9:00 CHAIR S INTRODUCTION 9:15 THE HUMAN MICROBIOTA AND BREAST CANCER: POSTMENOPAUSAL BREAST CANCER AND ESTROGEN ASSOCIATIONS WITH THE IGA- COATED AND IGA-NON-COATED FECAL MICROBIOTA - Discussing the influence of hormones on gut microbiota and the altered gut microbiota in postmenopausal women with breast cancer - Associations between gut bacteria and estrogen metabolite ratios James Goedert MD, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH 9:50 THE TUMOR MICROBIOME & THE ONCOGENIC PROPERTIES OF MICROBES 11:00 MICROBIAL SIGNATURES FOR THE PREDICTION & PREVENTION OF GYNAECOLOGIC CANCERS - Screening strategies to improve early diagnosis of uterine & cervical cancers - How can this assist in stratifying patients to determine the optimum therapy? - Could the microbiome be used as a drug target? Marina R Walther-Antonio, Ph.D., Assistant Professor of Surgery, Mayo Clinic 11:35 ACCURATE, RAPID, AND COMPREHENSIVE MICROBIOME PROFILING OF HEALTHY VS DISEASED STATES - How do changes in the microbial community and/or association of specific microbes associate with gastric, lung, oral, pancreatic, or cervical cancers Rita Colwell, Founder and Chair, CosmosID CosmosID is working with The White House Cancer Moonshoot Initiative to accelerate progress in cancer research - Exploring the prevalence of microbiota local to tumors - Microbiological signatures associated with malignancies - Strategies and challenges with identifying microbial pathogens in tumor tissues Erle Robertson, Professor in Otorhinolaryngology, University of Pennsylvania With over 20 years of experience researching the tumor microbiome, Erle Robertson is one of the pioneers of the oncobiome field. 12:10 SULFUR MICROBES AND HIGH CANCER RISK H Rex Gaskins, Professor of Immunobiology, Carl R. Woese Intitute of Genomic Biology; Cancer Centre at Illinois 12:45 LUNCH & NETWORKING BREAK

6 AGENDA DAY ONE AFTERNOON SESSION: MICROBIAL THERAPEUTICS 2:15 KEYNOTE PRESENTATION: ECOBIOTIC DRUGS MODULATING HUMAN IMMUNE RESPONSES: A POTENTIAL ROLE IN IMMUNO-ONCOOLOGY - Clinical study developing SER-401 oral microbiome therapy for patients with advanced metastatic melanoma David Cook, Executive Vice President of R&D and Chief Scientific Officer of Seres Therapeutics Seres is a pioneering biotech, developing the first therapeutics to catalyze a shift to health by augmenting the biology of the microbiome 2:45 UTILIZING CLOSTRIDIUM NOVYI BACTERIUM TO PRODUCE A STRONG AND PRECISELY TARGETED ANTI-TUMOR RESPONSE - Exploiting the hypoxic tumor microenvironment to develop novel therapeutic approaches to shrink tumors Shibin Zhou, Associate Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center Director, Experimental Therapeutics Ludwig Center for Cancer Genetics and Therapeutics Johns Hopkins University School of Medicine 3:20 CHEMOTHERAPY ADJUNCT FOR THE REDUCTION OF DOSE-LIMITING TOXICITY THROUGH THE TARGETING OF BACTERIAL BETA- GLUCURONIDASE - Core technology to enable identification of bacterial targets implicated in cancer Bret Wallace, scientist, Symberix Symberix is developing first-to-market drugs that selectively target the human microbiome to improve therapies 4:25 DEVELOPMENT OF DEFINED MICROBIAL DRUG PRODUCTS FOR CANCER IMMUNOTHERAPY - Using metagenomics & next-gen sequencing to create rationally selected consortia - Understanding the inter-microbial interactions to determine mechanisms of action Bruce Roberts, Chief Scientific Officer, Vedanta Biosciences 5:00 ORAL ABSTRACT PRESENTATION: METAGENOMIC BINNING AND ASSOCIATION OF PLASMIDS WITH BACTERIAL HOST GENOMES USING DNA METHYLATION Gang Fang, Assistant Professor, Icahn School of Medicine at Mount Sinai A real state of the art update of a rapidly changing and exciting area. Consultant General and Colorectal Surgeon, Vale Healthcare 3:50 NETWORKING BREAK

7 AGENDA DAY TWO MORNING SESSION: THE MICROBIOME INTERACTION WITH DRUGS & IMMUNO-THERAPY 8:00 REGISTRATION 10:25 BREAK 9:00 CHAIR S INTRODUCTION 9:15 DEVELOPMENT OF A 3D INTESTINE-CHIP MODEL: POTENTIAL FOR STUDYING HOST-MICROBIOME INTERACTIONS Dr. Jordan Kerns, Principal Investigator I, R&D Lead, Emulate Inc Emulate are working to create a new living system that emulates human biology to understand how different diseases, medicines, chemicals and foods affect human health 9:50 KEYNOTE PRESENTATION: THE IMPACT OF THE MICROBIOME ON IMMUNOTHERAPY: GUT MICROBIOME MODULATES RESPONSE TO ANTI PD-1 IMMUNOTHERAPY IN MELANOMA PATIENTS - What are the next steps needed to improve checkpoint inhibitor immuno-therapy? - Case study: predicting responders & non-responders at the bedside - Can we manipulate the microbiome before therapy to improve PD1 efficacy? Vancheswaran Gopalakrishnan, Wargo Lab, MD Anderson 11:00 MICROBIOME-DERIVED BIOACTIVE MOLECULES AS NEW SOURCE OF IMMUNOTHERPAPY FOR CANCER - What are the microbiome MoAs targeted? - Can microbial molecules act as specific activators of immune response? Rodolphe Clerval, CBO, Enterome 11:40 TRANSLATIONAL AND CLINICAL DEVELOPMENT OF CLOSTRIDIUM NOVYI-NT - Utilising C. novyi-nt to lyse malignant cells by secreting lipases, proteases, other hydrolytic enzymes, and recruiting inflammatory cells to elicit an anti-tumor immune response. Halle Zhang, Director of Translational Sciences & Clinical Development, BioMed Valley Discoveries, Inc. 12:15 LUNCH The understanding of the role of the microbiome in cancer is growing rapidly. The number of papers published in the field has increased ten-fold in just five years, from 83 in 2011 to 850 in 2017.

8 AGENDA DAY TWO AFTERNOON SESSION: DIAGNOSTICS & PREVENTION 1:45 PROBIOTIC MICROBE STRATEGIES FOR PREVENTION AND TREATMENT OF CANCER - Exploring the connection between gut microbes, the immune system with cancers throughout the body - Trans-generational effects of the microbiome on cancer risk Dr. Susan Erdman, Division of Comparative Medicine, Massachusetts Institute of Technology (MIT) 3:30 INDUCING GUT BACTERIA TO DIRECTLY INHIBIT COLORECTAL CANCER CELL GROWTH VIA PREBIOTIC (A.K.A. MICROFOOD ) INTERVENTION Jack Oswald, CEO & co-founder, ISOthrive 4:05 CHAIR S CLOSING REMARKS 2:55 APPLICATIONS OF THE MICROBIOME IN DEVELOPMENT OF IMMUNOONCOLOGY DRUGS Stefan Scherer, Vice President, Head Early Development, Strategy and Innovation Novartis POSTER PRESENTATIONS Showcase your research in our dedicated poster sessions. In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and posters space is assigned on a first come first served basis (subject to checks and successful registration). At the Congress, your presentation will be displayed in a dedicated poster area. Poster presentation sessions will take place both in the breaks. Poster abstract submission deadline is on 27 April. Posters should be sized A0 (841mm x 1189mm) in portrait orientation. For more details, and to submit your application visit

9 JOIN OUR NETWORK We believe that the inspiration and innovation needed to drive the microbiome industry forward comes only through connecting people and connecting ideas. Growing our community of microbiome researchers, entrepreneurs and industry leaders, sharing pioneering research and expertise around overcoming the barriers to translation of research into clinically and commercially viable therapeutics. SERIES - CALENDAR OF EVENTS FEBRUARY 5 th - 7 th San Diego, USA MARCH 21 th - 22 nd Kansas City, USA MAY 8 th - 9 th CANCER MICROBI ME CONGRESS Boston, USA MAY 23 rd London, UK MAY 29 th Boston, USA Website TBC JUNE Paris, France animalmicrobiomecongress.com NOVEMBER 27 th - 29 th

10 VENUE AND PRICING The Cancer Microbiome Congress is taking place in Boston, USA. Hilton Boston Dedham, 25 Allied Drive, Dedham, MA, 02026, USA Group Name: Oncobiome Congress BostonGroup Code: ONCArrival Date: 07-May- Departure Date: 09-May- Last Day to Book Rooms: April 6th, CLICK HERE TO BOOK Remember to always quote KISACO RESEARCH LTD when booking. T: PRICING INFORMATION BOOK A TEAM TO SAVE MORE! Industry Rates Only: Team discounts cannot be combined with any other discount or offer Book a Team of 3+ Save an Additional 10% Off PASS TYPE STANDARD PRICING Book a Team of 5+ Save an Additional 15% Off Academics and Clinicians $899 Pharmaceutical and Biotech $1,799 Payment Terms: Please note that a $79 USD processing fee will apply to any invoices requested. All prices are in US dollars All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above. No discount offers can be combined with any other offer Service Providers & Vendors $2,299 Please view our Cancellation Policy QUESTIONS? Please events@kisacoresearch.com INTERESTED IN SPONSORSHIP? Please contact Mark Gavhure, Manager Commercial Partnerships +44(0) mg@kisacoresearch.com